Part,  Chapter, Paragraph

  1    I,     2.  9        |           temperature has increased by 0.8 °C compared with pre-industrial
  2    I,     2.  9        |              land and oceans, and by 1.0 °C for land alone. Europe
  3    I,     2.  9        |             than the global average (1.0 and 1.2 °C, respectively),
  4    I,     2.  9        |          increases in Europe between 1.05.5 °C by the end of the
  5    I,     2.  9        |        projected global warming (1.84.0 °C).~ ~European glaciers
  6    I,     2.  9        |              risk increases by between 0.2 and 5.5 % for every 1
  7    I,     2. 10.  2    |            range between 1 and 100 nm (0.001-0.1 μm), are characterized
  8    I,     2. 10.  2    |            between 1 and 100 nm (0.001-0.1 μm), are characterized
  9    I,     2. 10.  4    |   administration errors (from 3.10% to 0.84%)11. Chelsea and Westminster
 10    I,     2. 10.  4    |            reduced by 67% from 2.7% to 0.9% of prescriptions12.~ ~
 11    I,     3.  1        |                was this number below 2.0. In several other EU Member
 12    I,     3.  1        |            States, the TFR was above 3.0: Cyprus, Ireland, Malta,
 13    I,     3.  1        |                State has a TFR above 2.0. This means that fertility
 14    I,     3.  3        |             pyramids depict persons of 0 to about 100 years of age,
 15    I,     3.  3        |             1963, this diminishes to 1.0% for those born in 2002,
 16    I,     3.  3        |      percentage of the population aged 0-14, 15-64 and 65+. They
 17    I,     3.  3        |                of EU27 population aged 0-14 and 65 or more from 1950
 18    I,     3.  3        |               a negative development (-0.4% per year) over the period
 19    I,     3.  3        |          ratios increase, varying from 0.3% for the United Kingdom
 20    I,     3.  3        |              annual growth varied from 0.6% to 1.0% over the periods
 21    I,     3.  3        |           growth varied from 0.6% to 1.0% over the periods from 1985
 22    I,     3.  3        |              can be noted:~ ~Children (0-14 years). Bulgaria, Italy,
 23   II,     4.  1        |              61.1 years for men and 63.0 years for women. These years
 24   II,     4.  1        |              and from 76.5 years to 84.0 years (7.5 years gap) for
 25   II,     4.  1        |             range respectively from 48.0 years to 68.5 years (20.
 26   II,     4.  1        |                years to 70.2 years (18.0 years gap) for women. Table
 27   II,     4.  2        |               years in the 1980s and 3.0 years in the 1990s. For
 28   II,     5.  2.  1    |              in Europe and more than 2.0 million deaths each year
 29   II,     5.  2.  3    |               100.000 in France to 327.0 deaths per 100.000 in Latvia,
 30   II,     5.  4.  1    |                fasting plasma sample 7.0 mmol/l (126 mg/dl) and /
 31   II,     5.  4.  1    |           global prevalence of about 6.0%, 46% of which in the 40-
 32   II,     5.  4.  1    |         equivalent to an increase of 1.0% in only 3 years. Very important
 33   II,     5.  4.  1    |          estimated to increase up to 8.0% in 2025.~Another important
 34   II,     5.  4.  2    |              by age/100,000 population 014 years~12~HES/HIS Registry~
 35   II,     5.  4.  2    |               of diabetes in children (0-14 year), with type 1 and
 36   II,     5.  4.  2    |               with HDL<1.15 mmol/l (<1.0 mmol/l)~11~Percent of diabetic
 37   II,     5.  4.  2    |          triglycerides >2.3 mmol/l (>2.0 mmol/l)~12~Percent of diabetic
 38   II,     5.  4.  2    |           above 6.1 mmol/l and below 7.0 mmol/l (fasting plasma glucose
 39   II,     5.  4.  2    |              glucose 6,1 mmol/l and <7,0 mmol/l).~Measurement of
 40   II,     5.  4.  2    |        reported here.~Level of HbA1c>7.0% is an indicator of poor
 41   II,     5.  4.  2    |               a value of HbA1c above 7.0%. This indicator is also
 42   II,     5.  4.  2    |               HDL cholesterol level <1.0 mmol/l for men and <1.25
 43   II,     5.  4.  2    |                HDL cholesterol below 1.0 for men and 1.25 mmol/l
 44   II,     5.  4.  3    |               of diabetes in children (0-14 year). Standardised incidence
 45   II,     5.  4.  3    |                8.5%) for children aged 0-4 years, 3.1% (1.5-4.8%)
 46   II,     5.  4.  3    |             for 5-9 years, and 2.4% (1.0-3.8%) for 10-14 years (Green,
 47   II,     5.  4.  3    |             Finland).~Level of HbA1c>7.0%. According to EUCID crude
 48   II,     5.  4.  3    |               HDL cholesterol level <1.0 mmol/l for men and <1.25
 49   II,     5.  4.  3    |             data, with figures between 0.1% (Netherlands, Sweden)
 50   II,     5.  5.Int    |             female subjects range from 0.1% to 5.7%, whilst for bulimia
 51   II,     5.  5.Int    |             for bulimia it ranges from 0.3% to 7.3% in women and
 52   II,     5.  5.Int    |              to 7.3% in women and from 0.1% to 2.1% in males. There
 53   II,     5.  5.Int    |                with active epilepsy is 0.9 million (prevalence 4.
 54   II,     5.  5.Int    |              million (prevalence 4.5-5.0 per 1000), 1.9 million aged
 55   II,     5.  5.Int    |           prevalence six per 1000) and 0.6 million aged 65 or older (
 56   II,     5.  5.  1    |                available in age groups 0-64 years and all ages. The
 57   II,     5.  5.  1    |            change estimated at -6.1%(P<0.0001), –5.4%(P<0.0001) and –
 58   II,     5.  5.  1    |                6.1%(P<0.0001), –5.4%(P<0.0001) and –5.0%(P<0.0001)
 59   II,     5.  5.  1    |                  5.4%(P<0.0001) and –5.0%(P<0.0001) respectively.~ ~
 60   II,     5.  5.  1    |               4%(P<0.0001) and –5.0%(P<0.0001) respectively.~ ~In
 61   II,     5.  5.  1    |                 respectively.~ ~In the 0-14 age group (Table 5.5.
 62   II,     5.  5.  2    |      population, the increase was from 0.44% to 1.25% (using EURODEM
 63   II,     5.  5.  2    |              percentage calculated was 0.83. Nevertheless, these
 64   II,     5.  5.  3    |                categories are observed 0 to 14 years and 15 to 19
 65   II,     5.  5.  3    |                separately in age group 0-14).~Finland~ ~X~ ~France~ ~
 66   II,     5.  5.  3    |             average prevalence rate of 0.3% for young females in
 67   II,     5.  5.  3    |                15-24-year-old females. 0.1% of young men are bulimic
 68   II,     5.  5.  3    |          Journal of Eating Disorder 00:0 000-000 2008-DOI 10.1002/
 69   II,     5.  5.  3    |            1000, lifetime prevalence 4.0 per 1000 and lifetime morbid
 70   II,     5.  5.  3    |               for period prevalence, 4.0 for lifetime prevalence
 71   II,     5.  5.  3    |             for lifetime prevalence is 0.5 to 1.0%.~Worldwide, between
 72   II,     5.  5.  3    |        lifetime prevalence is 0.5 to 1.0%.~Worldwide, between 16
 73   II,     5.  5.  3    |             thus the incidence rate is 0.016 to 0.042% with a broad
 74   II,     5.  5.  3    |             incidence rate is 0.016 to 0.042% with a broad variation
 75   II,     5.  5.  3    |              higher mortality rate (23.0% vs. 11.2%) was mainly the
 76   II,     5.  5.  3    |             value reported for Norway (0.0164). On the other hand,
 77   II,     5.  5.  3    |               3%~ONS United Kingdom 15.0%~OPCS United Kingdom 18.
 78   II,     5.  5.  3    |                 OPCS United Kingdom 18.0%~ ~According to the examination
 79   II,     5.  5.  3    |             104, of psychologists from 0.1 to 96 per 100 000 population (
 80   II,     5.  5.  3    |           cryptogenic epilepsies was 1.0 per 1,000. In another study
 81   II,     5.  5.  3    |               undetermined epilepsies (0.6 per 1,000). Localization-related
 82   II,     5.  5.  3    |           epilepsy 1-5%, West syndrome 0.5-8%, and Lennox-Gastaut
 83   II,     5.  5.  3    |                after seizure onset was 0.94 (95% CI 0.91-0.97), 0.
 84   II,     5.  5.  3    |         seizure onset was 0.94 (95% CI 0.91-0.97), 0.88 (95% CI 0.
 85   II,     5.  5.  3    |            onset was 0.94 (95% CI 0.91-0.97), 0.88 (95% CI 0.84-0.
 86   II,     5.  5.  3    |               0.94 (95% CI 0.91-0.97), 0.88 (95% CI 0.84-0.92), and
 87   II,     5.  5.  3    |               0.91-0.97), 0.88 (95% CI 0.84-0.92), and 0.75 (95%
 88   II,     5.  5.  3    |               0.97), 0.88 (95% CI 0.84-0.92), and 0.75 (95% CI 0.
 89   II,     5.  5.  3    |                 95% CI 0.84-0.92), and 0.75 (95% CI 0.74-0.86), respectively.~
 90   II,     5.  5.  3    |                0.92), and 0.75 (95% CI 0.74-0.86), respectively.~
 91   II,     5.  5.  3    |                  and 0.75 (95% CI 0.74-0.86), respectively.~Based
 92   II,     5.  5.  3    |               MF~Incident cohort~45~28.0~1.6~Olafsson et al., 1998~
 93   II,     5.  5.  3    |               Prevalent cohort~218~121.0~1.8~Zielinski, 1974~Sweden~
 94   II,     5.  5.  3    |     institution~Cross-sectional~105~12.0~8.7~Alstrom, 1942 (*)~ ~
 95   II,     5.  5.  3    |              incident cohort~4001~1109.0~3.6~Nilsson et al, 1997~
 96   II,     5.  5.  3    |           However, the PMRs range from 0 to 20% and the SMRs from
 97   II,     5.  5.  3    |        epilepsy and 75% in controls (p<0.0001). The cumulative probability
 98   II,     5.  5.  3    |                and 17% respectively (p<0.0001). Illnesses and accidents
 99   II,     5.  5.  3    |            extremely low, ranging from 0.02 to 0.2% (Black and Lay,
100   II,     5.  5.  3    |              low, ranging from 0.02 to 0.2% (Black and Lay, 1997;
101   II,     5.  5.  3    |         Disability Status Scale (EDSS) 0 to 3.5), moderate (4.0 to
102   II,     5.  5.  3    |                 0 to 3.5), moderate (4.0 to 6.5) and severe (7.0
103   II,     5.  5.  3    |                0 to 6.5) and severe (7.0 to 9.5).~Based on the clinical
104   II,     5.  5.  3    |               mean annual incidence of 0.9 for Romania. Prevalence
105   II,     5.  5.  3    |                range for mild MS (EDSS 0-3.5) was 33% (UK) to 80% (
106   II,     5.  5.  3    |            with mortality ranging from 0.6 to 1.0 per 100 000 as
107   II,     5.  5.  3    |        mortality ranging from 0.6 to 1.0 per 100 000 as reported
108   II,     5.  5.  3    |            with a woman:man ratio of 2.0. In the same study the total
109   II,     5.  5.  3    |              one of the 20 categories (0, 0.5, 1, etc. to 10) which
110   II,     5.  5.  3    |               of the 20 categories (0, 0.5, 1, etc. to 10) which
111   II,     5.  5.  3    |   cross-sectional studies so that EDSS 0 to 3.5 refers to fully ambulatory
112   II,     5.  5.  3    |               one functional system, 4.0-6.5 refers to fully ambulatory,
113   II,     5.  5.  3    |      assistance needed to walk 20 m; 7.0 to 9.5 refers to patients
114   II,     5.  5.  3    |               5 to 7.5/100.000; CGD: 4.0/100.000, respectively (Nath
115   II,     5.  6.  3    |               an odds ratio of about 8.0 for developing OA knee (
116   II,     5.  6.  3    |                from national data were 0.1% of 1991 GNP, of which
117   II,     5.  6.  3    |             ratio varied from 1.7 to 4.0) .~ ~The incidence of RA
118   II,     5.  6.  3    |              in Finland is reported as 0.6%, France 0.32% and Italy
119   II,     5.  6.  3    |               reported as 0.6%, France 0.32% and Italy 0.13%. In
120   II,     5.  6.  3    |                 France 0.32% and Italy 0.13%. In women, the prevalence
121   II,     5.  6.  3    |            same three countries is 1%, 0.86% and 0.51%. These figures
122   II,     5.  6.  3    |             countries is 1%, 0.86% and 0.51%. These figures are not
123   II,     5.  6.  3    |               per year among women and 0.6% per year among men from
124   II,     5.  6.  3    |            reported an incidence of 28.0 episodes / 1000 people per
125   II,     5.  6.  4    |         musculoskeletal conditions was 0.7% of the gross national
126   II,     5.  6.  6    | Musculoskeletal Health, ISBN 91-975284-0-4. Bone and Joint Decade
127   II,     5.  6.  6    |              and Risk Factors ISBN-10: 0-8213-6262-3. Oxford University
128   II,     5.  7.  1    |                for ESRD patients, i.e. 0.083% of the general population (
129   II,     5.  7.  3    |              for ESRD in children aged 0-14 was 7.1 patients pmarp (
130   II,     5.  7.  3    |               prevalence of RRT in the 0-14 years age group was 43
131   II,     5.  7.  3    |              the 65+ age group. In the 0-14 age group, however, the
132   II,     5.  7.  3    |              and 72% for patients aged 0-14, 15-64 and over 65 years
133   II,     5.  8.  2    |     obstructive) bronchitis ( J4 )~J43.0~ ~MacLeod's syndrome~ ~ ~
134   II,     5.  8.  2    |             external agents ( J6 )~J44.0~ ~Chronic obstructive pulmonary
135   II,     5.  8.  3    |               incidence of COPD was 11.0% according to the GOLD criteria (
136   II,     5.  8.  3    |            reported rates ranging from 0.23 to 18.3%, the lowest
137   II,     5.  8.  3    |                18.3%, the lowest ones (0.2 to 2.5%) being based on
138   II,     5.  8.  3    |        prevalence rates ranged from 11.0% with the ERS criterion (
139   II,     5.  8.  3    |              by 90% in females (from 1.0 to 2.9 per 1 000) from 2000
140   II,     5.  8.  3    |               2.2%, severe-very severe 0.4 and 0.3% (Zielinski et
141   II,     5.  8.  3    |             severe-very severe 0.4 and 0.3% (Zielinski et al, 2006).
142   II,     5.  8.  3    |              moderate 2.2%, and severe 0.6% (GOLD-COPD: mild 8.2%,
143   II,     5.  8.  3    |                  moderate 5.3%, severe 0.7%, and very severe 0.1%) (
144   II,     5.  8.  3    |           severe 0.7%, and very severe 0.1%) (Lindberg et al 2006).
145   II,     5.  8.  3    |           moderate, 3.7 for severe and 0.6 for very severe COPD (
146   II,     5.  8.  3    |              males and 3..9, 8.1, 2.3, 0.4, respectively, in females.~ ~
147   II,     5.  8.  3    |                relative risk (RR) = 16.0), osteoporosis (RR = 3.1),
148   II,     5.  8.  3    |            glaucoma (RR = 1.3) [all p <0.05].~ ~The Longitudinal
149   II,     5.  8.  3(27)|                Stage I:~Mild FEV1/FVC <0.70~FEV1 80% predicted~Stage
150   II,     5.  8.  3(27)|           Stage II:~Moderate FEV1/FVC <0.70~50% FEV1 <80% predicted~
151   II,     5.  8.  3(27)|            Stage III:~Severe FEV1/FVC <0.70~30% FEV1 <50% predicted~
152   II,     5.  8.  3(27)|              IV:~Very Severe FEV1/FVC <0.70~FEV1 <30% predicted or
153   II,     5.  8.  4    |             been developed (GOLD stage 0), 2.5 and 1.1% for GOLD
154   II,     5.  8.  5    |               16.3%, whereas it was 12.0% in those with normal spirometric
155   II,     5.  8.  5    |              spirometric parameters (p<0.001). In the second part,
156   II,     5.  8.  6    |              setting (41% vs. 12.5%, p<0.05) and to receive long-term
157   II,     5.  8.  6    |              home care (26% vs 9.7%, p<0.05), but were much less
158   II,     5.  8.  6    |             hospital (47.6% vs 5.1%, p<0.001) or at home (37.4% vs
159   II,     5.  8.  6    |              at home (37.4% vs 2.8%, p<0.05) than people with lung
160   II,     5.  9.  2    |              turbinate hypertrophy 478.0Allergic rhinitis due
161   II,     5.  9.  2    |             rhinitis due to pollen 477.0Allergic rhinitis due
162   II,     5.  9.  3    |             age at onset (62.8% and 15.0% in the <10- and > or =20-
163   II,     5.  9.  3    |             significant correlation (P<0.0001) between the prevalence
164   II,     5.  9.  3    |      remarkable in German children (p <0,05)~ ~The survey by Compalati
165   II,     5.  9.  3    |         billion) and inpatient care (€ 0.5 billion) (Lung Health
166   II,     5.  9.  4    |           narrowed for wheeze (1.34 to 0.98:1 P <0.0002), asthma (
167   II,     5.  9.  4    |              wheeze (1.34 to 0.98:1 P <0.0002), asthma (1.74 to 1.
168   II,     5.  9.  4    |              asthma (1.74 to 1.02:1 P <0.0001), eczema (1.42:1 to
169   II,     5.  9.  4    |               0001), eczema (1.42:1 to 0.81:1 P <0.0001) and hay
170   II,     5.  9.  4    |            eczema (1.42:1 to 0.81:1 P <0.0001) and hay fever (1.46
171   II,     5.  9.  4    |                 and hay fever (1.46 to 0.93:1 P <0.0001). The diagnosis
172   II,     5.  9.  4    |               fever (1.46 to 0.93:1 P <0.0001). The diagnosis of
173   II,     5.  9.  4    |              and/or hay fever RR 1.20 (0.99, 1.45). By 2004 this
174   II,     5.  9.  4    |               longer present, RR 1.01 (0.91, 1.12) for wheeze and
175   II,     5.  9.  4    |               12) for wheeze and 1.02 (0.85, 1.21) for those with
176   II,     5.  9.  4    |            risk=1.6, 95% CI 1.1-2.3, P=0.017). Risks were higher
177   II,     5.  9.  4    |              symptoms (2.4, 1.3-4.6, P=0.008). Among common occupations,
178   II,     5.  9.  4    |                for nursing (2.2, 1.3-4.0, P=0.007). Asthma risk was
179   II,     5.  9.  4    |               nursing (2.2, 1.3-4.0, P=0.007). Asthma risk was also
180   II,     5.  9.  4    |               spills (RR=3.3, 95% CI 1.0-11.1, P=0.051). The population-attributable
181   II,     5.  9.  4    |                3.3, 95% CI 1.0-11.1, P=0.051). The population-attributable
182   II,     5.  9.  4    |      rhino-conjunctivitis symptoms was 0.50 (95% confidence interval (
183   II,     5.  9.  4    |               confidence interval (CI) 0.38-0.65) and 0.53 for allergic
184   II,     5.  9.  4    |          confidence interval (CI) 0.38-0.65) and 0.53 for allergic
185   II,     5.  9.  4    |           interval (CI) 0.38-0.65) and 0.53 for allergic sensitization (
186   II,     5.  9.  4    |         allergic sensitization (95% CI 0.42-0.67) for farm children
187   II,     5.  9.  4    |             sensitization (95% CI 0.42-0.67) for farm children compared
188   II,     5.  9.  4    |               12.4% of the males and 8.0% of the females (P=0.03).
189   II,     5.  9.  4    |             and 8.0% of the females (P=0.03). Analysis by multiple
190   II,     5.  9.  4    |           female sex (odds ratio, OR = 0.5); presence of relatives
191   II,     5.  9.  4    |            initial years of life (OR = 0.6); attending day care (
192   II,     5.  9.  4    |               attending day care (OR = 0.4) and infant school (OR =
193   II,     5.  9.  4    |                and infant school (OR = 0.4); a positive association
194   II,     5.  9.  4    |      population-based sample of 17,641 0-to 17-year-olds, and blood
195   II,     5.  9.  4    |                time spent in Apulia (P=0.04 for hay-fever) (Ventura
196   II,     5.  9.  4    |              and 9.7% respectively, P <0.001; current wheeze: 5.2%
197   II,     5.  9.  4    |                6.9%, respectively, P = 0.04). Lower risks for lifetime
198   II,     5.  9.  4    |           prevalence odds ratio, POR = 0.39; 95% CI: 0.23-0.66) and
199   II,     5.  9.  4    |             ratio, POR = 0.39; 95% CI: 0.23-0.66) and current wheeze (
200   II,     5.  9.  4    |               POR = 0.39; 95% CI: 0.23-0.66) and current wheeze (
201   II,     5.  9.  4    |              and current wheeze (POR = 0.72; 95% CI: 0.47-1.10) were
202   II,     5.  9.  4    |            wheeze (POR = 0.72; 95% CI: 0.47-1.10) were found in children
203   II,     5.  9.  4    |               2.5-10 microm) and fine (0.15-2.5 microm) particles
204   II,     5. 10.  2    |               due to ingested food~995.0~Anaphylactic shock~995.1~
205   II,     5. 10.  2    |               Emphysema~493~Asthma~493.0~Asthma, extrinsic~493.1~
206   II,     5. 10.  2    |               due to ingested food~T78.0~Anaphylactic shock due to
207   II,     5. 10.  3    |         confirmed with food challenge (0.8-2.4%) (EU SCOOP, 1998).~ ~
208   II,     5. 11.  1    |               affecting around 22.533.0% of the European population (
209   II,     5. 11.  3    |          nickel and cobalt, whereas 7 (0.7%) had contact allergy
210   II,     5. 11.  3    |               gold sodium thiosulfate (0.78%) was found in 23 patients;
211   II,     5. 11.  3    |             nickel at a rate exceeding 0.5 µg/cm2 /week. It should
212   II,     5. 11.  3    |             should be noticed that the 0.5 µg Ni/cm2 /week release
213   II,     5. 11.  3    |             higher concentrations than 0.5 µg Ni/cm2 /week to be
214   II,     5. 11.  3    |             Among Danish children aged 018 , nickel allergy decreased
215   II,     5. 11.  3    |               prevalences ranging from 0.2% to 4.8%. The highest
216   II,     5. 11.  7    |        Prevalence Worldwide, Version 1.0. IARC Cancer-Base No. 5.
217   II,     5. 12.  3    |               38.7/100,000), Italy (35.0), France (30.9), as well
218   II,     5. 12.  3    |                to 19.4, Poland from 13.0 to 15.9, and mainly Hungary,
219   II,     5. 12.  7    |          Regression Program, version 3.0. Available at: htt ~ ~Negri
220   II,     5. 14.  3    |                figure for Denmark is 1.0 DMF-T.~ ~Table 5.14.1. Dental
221   II,     5. 14.  3    |              represented an average of 0.5% of the GDP, or approximately
222   II,     5. 14.  3    |              most for its oral health: 0.8% of the GDP. France falls
223   II,     5. 14.  3    |             devoted to health care and 0.5% reserved for dental care.
224   II,     5. 14.  3    |              for dental care. Finland (0.4%) and the Netherlands (
225   II,     5. 14.  3    |               4%) and the Netherlands (0.3%) have the smallest expenditures.~ ~
226   II,     6.  3.  1    |     attributable to norovirus was € 25.0 million, to campylobacteriosis €
227   II,     6.  3.  2    |               Latvia), but ranged from 06% in the rest of the countries.
228   II,     6.  3.  3    |              the lowest in Luxembourg (0.22 per 100 000), followed
229   II,     6.  3.  3    |                and Portugal (both with 0.42 per 100 000). However,
230   II,     6.  3.  3    |              increased steadily from 7.0 per 100 000 per year in
231   II,     6.  3.  4    |           observed among children aged 014 years. In all, the peak
232   II,     6.  3.  4    |                the 25 countries (range 078%). Most cases of foreign
233   II,     6.  3.  5    |               the youngest age groups (014 years).~ ~In 2005, a
234   II,     6.  3.  5    |               20) with an incidence of 0.87 per 100 000.~ ~Tetanus~ ~
235   II,     6.  3.  5    |                rates were always below 0.2 per 100 000 per year in
236   II,     6.  3.  5    |             incidence rates were below 0.35 per 100 000 per year,
237   II,     6.  3.  5    |        Slovenia where incidence was at 0.45 per 100 000 per year
238   II,     6.  3.  5    |              cases) and for Malta with 0.5 per 100 000 per year in
239   II,     6.  3.  5    |         incidence rates were in Malta (0.25 per 100 000), followed
240   II,     6.  3.  5    |               000), followed by Italy (0.11 per 100 000).~ ~
241   II,     6.  3.  5    |                incidence in the EU was 0.28 per 100 000 per year
242   II,     6.  3.  5    |            Ireland (2.26) and Germany (0.94). Elimination has not
243   II,     6.  3.  5    |              The overall incidence was 0.51 per 100 000 per year,
244   II,     6.  3.  6    |              reported in the age group 04 years (27% of cases),
245   II,     6.  3.  6    |                countries. Norway, with 0.87 per 100 000, reported
246   II,     6.  3.  6    |              rate, followed by the UK (0.79 per 100 000).~ ~Shigellosis~ ~
247   II,     6.  3.  6    |                age group appears to be 04 year one. In 2005, a total
248   II,     6.  3.  6    |                 The incidence in 2004 (0.28 per 100 000 per year)
249   II,     6.  3.  6    |                cases in 2005. Denmark (0.85 per 100 000), followed
250   II,     6.  3.  6    |             000), followed by Finland (0.69 per 100 000) reported
251   II,     6.  3.  6    |                just under 4 000 cases (0.87 per 100 000)) to 2004 (
252   II,     6.  3.  6    |                  to 2004 (1 743 cases (0.38 per 100 000)). Twenty-six
253   II,     6.  3.  6    |                an overall incidence of 0.31 per 100 000. Portugal (
254   II,     6.  3.  6    |       reporting the highest incidence (0.15 per 100 000).~ ~Cholera~ ~
255   II,     6.  3.  6    |              237 cases were reported ( 0.01 per 100 000 per year).
256   II,     6.  3.  6    |               22 countries. Lithuania (0.44 per 100 000), followed
257   II,     6.  3.  6    |                  followed by Slovenia (0.30 per 100 000), reported
258   II,     6.  3.  6    |                 followed by Lithuania (0.35 per 100 000) reported
259   II,     6.  3.  7    |             000), followed by Hungary (0.86 per 100 000) reported
260   II,     6.  3.  7    |                death rate of less than 0.5%. This disease is the
261   II,     6.  3.  7    |               the rate varying between 0.2 and 0.5 cases per 100
262   II,     6.  3.  7    |                varying between 0.2 and 0.5 cases per 100 000. In
263   II,     6.  3.  7    |               highest incidence rates (0.49 per 100 000 and 0.48
264   II,     6.  3.  7    |            rates (0.49 per 100 000 and 0.48 per 100 000, respectively).
265   II,     6.  3.  7    |                19952004, ranging from 0.1 to 0.22 cases per 100
266   II,     6.  3.  7    |              2004, ranging from 0.1 to 0.22 cases per 100 000. The
267   II,     6.  3.  7    |               countries, with Estonia (0.82 per 100 000) followed
268   II,     6.  3.  7    |               000) followed by France (0.77 per 100 000) reporting
269   II,     7.  3.  4    |              the EU27. They range from 0.3 per 100 000 inhabitants
270   II,     7.  7        |               com/csi/eurosafe2006.nsf/0/EE9D475AA6DAF58BC125747200411F14/$
271   II,     8.  2.  1    |           countries is in the range of 0.3-0.4% for severe mental
272   II,     8.  2.  1    |       countries is in the range of 0.3-0.4% for severe mental retardation (
273   II,     8.  2.  1    |            adults has been found to be 0.36% in whites and 0.32%
274   II,     8.  2.  1    |              to be 0.36% in whites and 0.32% in South Asian residents
275   II,     8.  2.  1    |                the population is about 0.44%, and that of mild to
276   II,     8.  2.  1    |            between 71 and 85) equal to 0.6%, 0.6% and 1.4%, respectively.
277   II,     8.  2.  1    |              71 and 85) equal to 0.6%, 0.6% and 1.4%, respectively.
278   II,     8.  2.  1    |           present with a prevalence of 0.32% (Rantakallio and von
279   II,     8.  2.  1    |       disability (SPID) in Finland was 0.13% based on the register
280   II,     8.  2.  1    |           severe mental retardation of 0.34% (Bersen, 1976).~ ~Prevalence
281   II,     8.  2.  2    |                a total prevalence of 2.0%, with 1.0% for people aged
282   II,     8.  2.  2    |             prevalence of 2.0%, with 1.0% for people aged 5 to 39,
283   II,     8.  2.  2    |                a total prevalence of 2.0%, with 1.0% for people aged
284   II,     8.  2.  2    |             prevalence of 2.0%, with 1.0% for people aged 5 to 39,
285   II,     8.  2.  3    |             tones of four frequencies: 0.5, 1, 2, and 4 kHz (WHO,
286   II,     8.  2.  3    |             ear) has been estimated as 0.1% in a study carried out
287   II,     8.  2.  3    |             about 553000 children aged 0-9 years (Fortnum and Davis,
288   II,     8.  2.  3    |                3% showed 45 dB HL, and 0.2% showed 65 dB HL. Hearing
289   II,     8.  2.  3    |             males/females in the range 0.9-1.2), with some evidence
290   II,     8.  2.  3    |               has been estimated to be 0.1 to 0.2%.~ ~Table 8.5.
291   II,     8.  2.  3    |            been estimated to be 0.1 to 0.2%.~ ~Table 8.5. Estimated
292   II,     9.  1.  1    |              early neonatal deaths (at 0-6 days after live birth)
293   II,     9.  1.  1    |              The number of deaths (day 0-364) after live birth at
294   II,     9.  1.  1    |               European countries, is 2.0 per 1 000 live births. As
295   II,     9.  1.  2    |                the EU-15 countries, 35.0% of the EU-NMS countries
296   II,     9.  1.  2    |              nervous system defects (2.0 per 1 000). EUROCAT updates
297   II,     9.  1.  2    |               a total prevalence above 0.1 per 1 000 births are shown
298   II,     9.  1.  2    |             with congenital anomaly is 0.43 per 1 000 births, and
299   II,     9.  1.  2    |               deaths in the first week 0.55 per 1 000 births, giving
300   II,     9.  1.  2    |               to congenital anomaly of 0.99 per 1 000 births (Table
301   II,     9.  1.  2    |           rates are recorded in Italy (0.2 per 1 000) but there is
302   II,     9.  1.  2    |            TOPFA to births varies from 0 (Ireland and Malta) to 11.
303   II,     9.  1.  2    |         anomaly (Table 9.1.2.3). Up to 0.8% (Switzerland) of foetuses
304   II,     9.  1.  2    |          countries record a rate above 0.5% (Table 9.1.2.3). The
305   II,     9.  1.  2    |         declined (Figure 9.1.2.2) to 1.0 per 1 000 births as the
306   II,     9.  1.  2    |                in Europe, ranging from 0.4 per 1 000 to 2.0 per 1
307   II,     9.  1.  2    |                from 0.4 per 1 000 to 2.0 per 1 000 (the high rates
308   II,     9.  1.  2    |           birth prevalence rates, from 0.1 per 1 000 in France and
309   II,     9.  1.  2    |               in France and Spain to 1.0 per 1 000 in Poland (Table
310   II,     9.  1.  2    |         EUROCAT, 2007), while rates of 0.6 per 1 000 or below were
311   II,     9.  1.  2    |               an average prevalence of 0.2 per 1 000 births in 2000-
312   II,     9.  1.  2    |               prevalenceSicily at 3.0 per 1 000, and Malta at
313   II,     9.  2.  2    |                produced for those aged 0-14 years inclusive, or those
314   II,     9.  2.  2    |               inclusive, or those aged 0-19 years inclusive. Children
315   II,     9.  2.  2    |          totality, namely persons aged 0-17 years inclusive, can
316   II,     9.  2.  2    |               additional tabulation of 0-17 years is usually not
317   II,     9.  2.  2    |               population. The use of a 0-19 years category results
318   II,     9.  2.  2    |             generally being those aged 0-14 years (from birth to
319   II,     9.  2.  3    |                cancer in children aged 0-14 in selected EUGLOREH
320   II,     9.  2.  3    |                cancer in children aged 0-14 in selected EUGLOREH
321   II,     9.  2.  3    |              supply data ranged from 3.0% in Romania and 3.7% in
322   II,     9.  3.  1    |           related to transport. In the 0-19 age range, the rate of
323   II,     9.  3.  1    |                with active epilepsy is 0.9 million children and adolescents (
324   II,     9.  3.  1    |          adolescents (prevalence 4.55.0 per 1000), 1.9 million aged
325   II,     9.  3.  1    |       prevalence about 6 per 1000) and 0.6 million aged 65 or older (
326   II,     9.  3.  1    |       increasing from 2.1 to 4.6 to 16.0 per 100 000 population across
327   II,     9.  3.  1    |              with an infection rate of 0.1% in the Northern Member
328   II,     9.  3.  1    |              off is 5 ng/dl (50 pg/ml)(0.17 nmol/L).~ ~In a joint
329   II,     9.  3.  1    |              arthritis affects between 0.5 and 1.0% of the adult
330   II,     9.  3.  1    |              affects between 0.5 and 1.0% of the adult population
331   II,     9.  3.  1    |                estimated to be between 0.1 and 3.3% in women between
332   II,     9.  3.  2    |               estimates ranging from 1.0 to 10.1 per 1 000 deliveries,
333   II,     9.  3.  2    |              of pregnancy, ranges from 0.07-8.23% with a case-fatality
334   II,     9.  3.  2    |       case-fatality ratio ranging from 0.02-37%.~ ~Severe maternal
335   II,     9.  3.  3    |                at least once, and only 0.9% said they had sexual
336   II,     9.  3.  3    |           review. Eur J Public Health. 0: ckm014v1-7~Johnson A, Mercer
337   II,     9.  4.  3    |            more by the population aged 0-14 years [per 100]) shows
338   II,     9.  5.  3    |              in 2004 was in Poland (32.0) and the Netherlands (30.
339  III,    10.  2.  1    |              ages who had BACs between 0.2g/l and 0.49g/l had at
340  III,    10.  2.  1    |                BACs between 0.2g/l and 0.49g/l had at least a three
341  III,    10.  2.  1    |               times with a BAC between 0.5g/L and 0.79g/L and 11
342  III,    10.  2.  1    |               a BAC between 0.5g/L and 0.79g/L and 11 times with
343  III,    10.  2.  1    |               times with a BAC between 0.8g/l and 0.99 g/L.~There
344  III,    10.  2.  1    |               a BAC between 0.8g/l and 0.99 g/L.~There is a relationship
345  III,    10.  2.  1    |                1.3% of all exports and 0.3% of all imports, thereby
346  III,    10.  2.  1    |                 i.e. as low as zero or 0.2g/l in a number of countries
347  III,    10.  2.  1    |                number of countries and 0.5g/l or lower in most countries
348  III,    10.  2.  1    |            range in prevalence between 0 and 10%).~ ~Overall prevalence
349  III,    10.  2.  1    |            ecstasy use was reported by 0 to 8% of school children
350  III,    10.  2.  1    |         Amphetamines have been used by 0 to 7% of school children,
351  III,    10.  2.  1    |      prevalence of LSD use ranges from 0.3% to 7.6%.~ ~Figure 10.
352  III,    10.  2.  1    |              typically ranging between 0.5 and 6 cases per year for
353  III,    10.  2.  1    |             may be around 1.1 million (0.91.3 million) injectors
354  III,    10.  2.  1    |             decreased by an average of 0.2% annually over 2001-2005,
355  III,    10.  2.  1    |          Special Eurobarometer Wave 62.0: The citizens of the European
356  III,    10.  2.  1    |            Eurobarometer 213 / Wave 62.0: The citizens of the European
357  III,    10.  2.  1    |                adults with a BMI of 25.0-29.9 kg/m2 (WHO, 2000).
358  III,    10.  2.  1    |              age groups; children aged 0-9 years; adolescents aged
359  III,    10.  2.  1    |             reported in Table 10.2.1.7.0.~ ~Table 10.2.1.7.0 Preliminary
360  III,    10.  2.  1    |                1.7.0.~ ~Table 10.2.1.7.0 Preliminary information
361  III,    10.  2.  1    |               in the Czech Republic (9.0%, both sexes 14-17 years
362  III,    10.  2.  1    |         greater proportion of boys (17.0%) than girls (14.3%) being
363  III,    10.  2.  1    |                et al, 2006), Wales (61.0%) (UK) (Dolman et al, 2007)
364  III,    10.  2.  1    |               et al, 2005); Latvia (42.0%) (Pudule et al, 2005),
365  III,    10.  2.  1    |                found in Wales (UK) (51.0%) (Dolman et al, 2007),
366  III,    10.  2.  1    |                and between 8.9% and 26.0% among women.~ ~Figure 10.
367  III,    10.  2.  1    |               risen rapidly: more than 0.7 and more than 1.0 percentage
368  III,    10.  2.  1    |               than 0.7 and more than 1.0 percentage points per year (
369  III,    10.  2.  1    |             men were in Spain (1.2 and 0.9 pp/y in women and men
370  III,    10.  2.  1    |        Kelleher et al, 2003), Denmark (0.9 and 0.7 pp/y, respectively,
371  III,    10.  2.  1    |                2003), Denmark (0.9 and 0.7 pp/y, respectively, from
372  III,    10.  2.  1    |             Health, 2001) and Hungary (0.6 percentage points for
373  III,    10.  2.  1    |             obesity in children aged 6.0-9.9 years in order to have
374  III,    10.  2.  4    |                tests (i.e., tests with 0-100% probability being a
375  III,    10.  3.  1    |           frequency (ELF), and static (0 Hz) (only static magnetic
376  III,    10.  3.  1    |        Frequency magnetic fields (ELF, 0<f 300 Hz) the previous conclusion
377  III,    10.  3.  1    |             limited to exposures above 0.4 µT. In European countries,
378  III,    10.  3.  1    |              per million children (age 0-14) per year. Whether changes
379  III,    10.  3.  2    |         sensitisation can be as low as 0.05μg/m3 air for previously
380  III,    10.  3.  2    |         tributyltin oxide is as low as 0.00025 mg/kg bodyweight per
381  III,    10.  3.  4    |                 emissions will only be 0.6% below base-year levels
382  III,    10.  4.  2    |        drinking water~Salmonellosis~35.0 per 100 000~Decreasing in
383  III,    10.  4.  2(34)|           detected in pigs varied from 0% to 29% between EU Member
384  III,    10.  4.  2    |              PFC were found in trouts: 0.02µg/g fish based on a TDI (
385  III,    10.  4.  2    |             Tolerable daily intake) of 0.1µg PFOS/kg body weight (
386  III,    10.  4.  2    |            showed an average intake of 0.13µg/kg bw (EFSA, 2006).~ ~
387  III,    10.  4.  2    |                in monitoring analyses (0.01mg/kg). For the remaining
388  III,    10.  4.  2    |         children and sets the level at 0.01mg/kg, again the limit
389  III,    10.  4.  2    |              with a reporting limit of 0.05 mg/kg. With the development
390  III,    10.  4.  2    |              with a reporting limit of 0.01 mg/kg. The wider introduction
391  III,    10.  4.  2    |         tributyltin oxide is as low as 0. 00025 mg/kg body weight
392  III,    10.  4.  2    |                ADI values for nitrate (0-3.7 mg/kg b.w) and nitrite (
393  III,    10.  4.  2    |                mg/kg b.w) and nitrite (0-0.07 mg/kg b.w) (FAO/WHO,
394  III,    10.  4.  2    |              mg/kg b.w) and nitrite (0-0.07 mg/kg b.w) (FAO/WHO,
395  III,    10.  4.  2    |             the~Netherlands is approx.~0.03 ng/kg body weight per~
396  III,    10.  4.  2    |        substances);~· A default MRL of 0,01 mg/kg applies to all
397  III,    10.  4.  2    |              pp. 130. ISBN 29-9199-000-0~ ~EFSA (2006b): Summary
398  III,    10.  4.  3    |              years of age fell from 70.0 (per 100 000) to 21.6 in
399  III,    10.  4.  3    |               same period dropped from 0.64 to 0.36.~ ~The information
400  III,    10.  4.  3    |            period dropped from 0.64 to 0.36.~ ~The information on
401  III,    10.  4.  3    |                chemical contamination (0.1% of cases of illness),
402  III,    10.  4.  3    |        microbial agent was implicated (0.8% of the cases of illness).
403  III,    10.  4.  5    |               between countries – from 0.3 tonnes per capita in Moldova
404  III,    10.  4.  5    |               comprising approximately 0.5%. In 2003, the WHO exposure
405  III,    10.  5.  2    |         illness, the Odds Ratio was at 0.93 for intermediate settings
406  III,    10.  5.  2    |           intermediate settings and at 0.81 for rural settings when
407  III,    10.  5.  2    |              data were rather similar (0.94 and 0.81, respectively)
408  III,    10.  5.  2    |               rather similar (0.94 and 0.81, respectively) also for
409  III,    10.  5.  2    |               www.oecd.org/document/61/0,3343,en_2649_37429_38690301_
410  III,    10.  5.  3    |          insured people varied between 0.7 million Euro for Austria
411  III,    10.  5.  3    |             reached 56.3% in the EU25 (0.7 points below the Stockholm
412  III,    10.  5.  3    |                among countries, from 2.0% in Slovakia to 49.8% in
413  III,    10.  5.  3    |               working full-time and 20.0 hours for those working
414  III,    10.  5.  3    |           which 48.9% were women and 8.0% were people aged 55-64).~·
415  III,    10.  5.  3    |                GDP. Estimates expect 2.0 million work-related deaths
416  III,    10.  6.  3    |              from females. On average, 0.5% of male respondents recorded
417   IV,    11.  1.  5    |             health systems ranked from 0 (least satisfied) to 8 (
418   IV,    11.  2.  1    |             2004 (thus, a reduction of 0.72 hospitals), compared
419   IV,    11.  2.  1    |             compared to a reduction in 0.89 hospitals in the EU15
420   IV,    11.  2.  1    |                EU15 and an increase of 0.8. hospitals in the new
421   IV,    11.  2.  2    |        prevention accounting for about 0.7% in Italy, to 4.7% in
422   IV,    11.  6.  2    |              have fallen from 11.8% to 0.75% of gross earnings.This
423   IV,    12.  2        |                1.3% of all exports and 0.3% of all imports, thereby
424   IV,    12.  2        |               and is as low as zero or 0.2g/l in a number of countries,
425   IV,    12.  2        |               number of countries, and 0.5g/l or lower in most countries
426   IV,    12. 10        |            limits on drunk driving are 0,03 % (possible legal consequences)
427   IV,    12. 10        |                legal consequences) and 0,05 % (lower limit for infringement
428   IV,    13.Acr        |        prevention accounting for about 0.5% of total health spending
429   IV,    13.Acr        |                spending in Denmark and 0.6% in Italy, to 4.9% in
430   IV,    13.  2.  1    |              has a weighting factor of 0.5, this means that a year
431   IV,    13.  2.  2    |                    Among children aged 0-4 years, living in the WHO
432   IV,    13.  2.  3    |            study made on children aged 0-4 years living in the WHO-Europe
433   IV,    13.  7.  3    |              The “Healththeme (EUR 6.0 billion) currently covers